CollPlant Biotechnologies (CLGN) Total Non-Current Liabilities (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Total Non-Current Liabilities came in at $2.0 million in Q4 2025, down 10.68% YoY from $2.3 million in Q4 2024, and down 5.58% on a QoQ basis from $2.2 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Total Non-Current Liabilities data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 10.68% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 10.68% YoY) and the FY2025 annual result came in at $2.0 million, down 10.68% from the prior year.
- Total Non-Current Liabilities retreated to $2.0 million in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.1 million in Q4 2021 to a low of $2.0 million in Q4 2025.
- A 5-year average of $2.5 million and a median of $2.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 11.77% in 2022, down 22.89% in 2022.
- Tracing CLGN's Total Non-Current Liabilities over 5 years: stood at $3.1 million in 2021, then declined by 22.89% to $2.4 million in 2022, then gained by 6.42% to $2.5 million in 2023, then slipped by 10.26% to $2.3 million in 2024, then decreased by 10.68% to $2.0 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $2.0 million (Q4 2025), $2.2 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Sep 30, 2023 | 2.53 Mn |
| Jun 30, 2023 | 2.75 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 3.09 Mn |
| Sep 30, 2021 | 2.64 Mn |
| Jun 30, 2021 | 2.65 Mn |
| Mar 31, 2021 | 2.61 Mn |
| Dec 31, 2020 | 2.98 Mn |